Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax bioavailability and food effect study in healthy females
NCT06742086Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of venetoclax (6 arms), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at 18 months, Maximum Observed Plasma Concentration at 18 months and 5 more. Started Dec 2024; status: completed.
02
Drugs
venetoclax
Beyond the preview
Go deeper on NCT06742086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742086.